

∧PTORUM

OUR MISSION IS TO FACILITATE LIFE SCIENCE INNOVATIONS TO SERVE UNMET MEDICAL NEEDS

Corporate Presentation

NASDAQ Global Market: APM

DISCLAIMER

Certain information included in this presentation and other statements or materials published by Aptorum Group Limited (the "Company") are not historical facts but are forward-looking statements.


These forward-looking statements refer in particular to the Company's management's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. Forward-looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice. Such forward looking statements are for illustrative purposes only. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company. These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.

A detailed description of risks and uncertainties related to the Company's activities is included under the "Risk factors" section of the Company's Prospectus (File No. 333-227198) filed with the Securities and Exchange Commission on December 4, 2018 and is available on the Company's website (www.aptorumgroup.com). This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company's business and markets. Such information is based on the Company's analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports. The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts. Such data and forecasts are included in this presentation for information purposes only.

This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in the United States or any other jurisdiction. This presentation includes only summary information and does not purport to be comprehensive. No reliance should be placed on the accuracy or completeness of the information or opinions contained in this presentation.

APTORUM SUMMARY

3



* Decisions on whether to continue development and commercialization of our early-stage projects would heavily depend on the relevant preclinical and clinical data and trial results. The Company expects to follow the business model outlined above.

LEADERSHIP



MR. IAN HUEN Founder, Chief Executive Officer and Executive Director

- Over 15 years in global asset management
- US healthcare equity research analyst at Janus Henderson Group
- Trustee board member of Dr. Stanley Ho Medical Development Foundation
- CFA, Princeton University (Econ)



MR. DARREN LUI President, Chief Business Officer and Executive Director

- Over 13 years in global capital market
- Extensive exposure in UK, Singapore, US.
- ICAS, CFA & Associate of Chartered Institute of Securities & Investments (UK)
- First-Class Honors from Imperial College (Biochemistry)



MISS SABRINA KHAN

Chief Financial Officer

- Almost 10 years serving US & Asian healthcare companies
- Extensive experience in business development, restructuring, US & Asian IPO, and M&A deals
- Solid accounting experience gained from Big 4
- Advanced China Certified Taxation Consultant
- CPA, the University of Hong Kong (BBA(Acc & Fin))



DR. CLARK CHENG

- Chief Medical Officer and Executive Director
- Almost 10 years working in Raffles Medical Group as Operations Director and Deputy General Manager
- Received medical training at the University College London in 2005 & obtained membership of the Royal College of Surgeons of Edinburgh in 2009
- MBA, University of Iowa



DR. THOMAS LEE WAI YIP

Chief Executive Officer & Chief Scientific Officer - Aptorum Therapeutics Limited

- Former Assistant Professor at The Chinese University of Hong Kong (CUHK) specialized in drug delivery and formulation development
- 10 years working at Novartis & Celgene
- B.Pharm.(Hons), CUHK; Ph.D. in Pharmaceutical Sciences (Drug Delivery), the University of Wisconsin-Madison

PROJECT PORTFOLIO

DRUG AND DEVICE CANDIDATES										
			DEVELOPMENT STAGE							
PROJECTS	CANDIDATE / MODALITY			Lead Discovery	Lead Optimization	IND-Enabling	Phase 1	Phase 2	Phase 3	
VIDENS' SERIE	ES									
VLS-1	Curcumin-MNP (Medical Imaging Agent for MRI Diagnosis)	Diagnosis of Alzheimer's Disease								
VLS-2	MITA (mTor-independent TFEB activator)	Treatment of Alzheimer's & Parkinson's Disease								
VLS-3	Non-Invasive Retina Imaging Diagnostics	Diagnosis of Alzheimer's Disease								
VLS-4	Imaging Agent for MRI Diagnosis	Diagnosis of Alzheimer's Disease								
ACTICULE'S S	ERIES									
ALS-1	Small Molecule	Treatment of viral infections caused by Influenza virus A								
ALS-2	Small Molecule	Treatment of bacterial infections caused by Staphylococcus aureus including MRSA								
ALS-3	Small Molecule	Reviving existing antibiotics to overcome drug resistance								
ALS-4	Small Molecule	Treatment of bacterial infections caused by Staphylococcus aureus including MRSA								

Lead Projects

Device Candidates

• Other Candidates



PROJECT PORTFOLIO

					DEVE	LOPMENT S	STAGE		
PROJECTS	CANDIDATE / MODALITY			Lead Discovery	Lead Optimization	IND-Enabling	Phase 1	Phase 2	Phase 3
NATIVUS' SERIES									
NLS-1	Small molecule	Treatment of Endometriosis							
NLS-2	An extract from Chinese yam	Relief of Menopausal Symptoms							
NLS-3	SAC	Treatment of and protection against retinal ischemia/ reperfusion injury							
SCIPIO'S SERIE	ES								
SPLS-1	83b-1 Novel Quinoline Derivative	Treatment of liver cancer							

			DEVELOPMENT STAGE						
PROJECTS CANDIDATE / MODALITY		INDICATION	Lab-based Phantom Trial	Animal Trial	IDE Application Approval	Safety/Fesibility Clinical Study	Pivotal Clinical Study	Process of obtaining PMA	
SIGNATE'S SERIES									
SLS-1Robotic catheter platform for Intra-operative MRI-guided cardiac catheterizationHeart rhythm disorders by cardiac electrophysiology intervention		On-going							

Lead Projects

6


Other Candidates Device Candidates

	OTHER KEY PROJECTS								
ALS-DDC	Drug Discovery Center + Chemical Library	Setting Up							
AML Clinic	Clinic - Talem Medical	Medical Services	Commenced operations in June 2018						



OVERVIEW OF OUR LEAD PROJECTS







ALS-1 INFLUENZA A	ALS-4 STAPHYLOCOCCUS INCLUDING METHICILLIN-RESISTANT S. AUREUS (MRSA)	NLS-1 ENDOMETRIOSIS
Population affected: Annual epidemics estimated to result in ~3-5 million cases of serious influenza infections, causing about 290,000-650,000 deaths each year ⁱ , around 50-80% of influenza infections are type A ⁱⁱ .	Population affected: 53 million people worldwide carry MRSA ¹ . For example, in U.S., ~126,000 hospitalizations are due to MRSA yearly, where severe infections occur in ~94,000 people each year and are associated with ~19,000 deaths ¹¹ .	Population affected: ~176 million women globally (≈1 in 10 women during their reproductive years) ⁱ . ~30-40% of women with endometriosis are subject to risk of infertility and may develop complications during pregnancy ⁱⁱ .
Market Size: Global Market Size in 2016: US\$ 0.60 billion ^{III} . Expected Global Market Size by 2025: US\$ 1.2 billion ^{III} .	Market Size: Global Market Size in 2016: US\$ 2.97 billion ^{III} . Expected Global Market Size by 2025: US\$ 3.91 billion ^{III} .	Market Size: Market Size in 2015: US\$ 1.72 billion (across the 7 major countries) ^{III} . Expected Market Size by 2025: just over US\$ 2 billion (across the 7 major countries) ^{III} .
 i.WHO: Influenza (Seasonal), <u>http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)</u> ii.WHO Global circulation of influenza viruses, <u>http://apps.who.int/flumart/Default?ReportNo=6</u> iii.Bloomberg: New Drugs Are Coming to Fight Nasty Flu Seasons (9 Feb 2018), <u>https://www.bloomberg.com/news/articles/2018-02-08/flu-relief-is-coming-as-successors-to-aging-tamiflu-near-market</u> 	i. Roche Annual report 2017, <u>https://www.roche.com/dam/jcr:78519d71-10af-4e02-b490-7b4648a5edb8/en/ar17e.pdf</u> iiemedicinehealth: MRSA <u>https://www.emedicinehealth.com/mrsa_infection/article_em.htm#how_common_is_mrs_a</u> iii. Healthcare Drive: Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast Predictions, <u>https://www.healthcaredive.com/press-release/20180405-global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-anal/</u>	 i.Endometriosis.org: Facts about endometriosis, <u>http://endometriosis.org/resources/articles/facts-about-endometriosis/</u> ii.Washington University Physicians, "Endometriosis", <u>https://fertility.wustl.edu/getting-started-infertility/infertility-factors/endometriosis/</u> J. Fisher M. Kirkman, "Endometriosis and fertility: women's accounts of healthcare", Human Reproduction, Volume 31, Issue 3, March 1, 2016, Pages 554–562, January 11, 2016, <u>https://doi.org/10.1093/humrep/dev337</u> iii. R&D: Endometriosis Market Expected to Surpass \$2 Billion by 2025 (11 Nov 2016) – By Global Data. List of 7 major countries: the US, France, Germany, Italy, Spain, the UK and Japan, <u>https://www.rdmag.com/news/2016/11/endometriosis-market-expected-surpass-2-</u>




7



Treatment of Bacterial Infections including MRSA by a Non-antibiotic Approach





- Bacterial infections are mediated by pathogenic or opportunistic bacteria
- Successful infections depends on host's immunity and pathogen's virulence
- Targeting bacterial virulence is an alternative approach to antimicrobial therapy

The figure is modified from Rachel J. Gordon, et al. Clin Infect Dis. (2008)



ALS-4: THE ADVANTAGE OF TARGETING VIRULENCE EXPRESSION-

DISARMING THE BACTERIA


✓ Avoid Bacterial Drug Resistance ✓ Preserve Host Normal Flora

Antibiotics

- Antibiotics are usually broad spectrum and indiscriminate
- Commonly affect normal flora, may lead to super-infection in case of drug resistance

Non-antibiotics

- Not bactericidal, no selective pressure to promote drug resistance
- Pathogen specific, avoid normal flora casualties
- Only reduce pathogenicity of bacteria, bacterial clearing is mediated by host immunity




Sources

- 1. Köhler T, Perron GG, Buckling A, van Delden C. PLoS Pathog.2010 May 6;6(5):e1000883.
- 2. Yu X-Q, Robbie G J, Wu Y, Esser M T, Jensen K, Schwartz H I, Bellamy T, Hernandez-Illas M, Jafri H S. Antimicrob Agents Chemother. 2017;61:e01020–16.
- 3. Milla C E, Chmiel J F, Accurso F J, VanDevanter D R, Konstan M W, Yarranton G, Geller D E. Pediatr Pulmonol. 2014;49:650–658.
- 4. DiGiandomenico A, Keller A E, Gao C, Rainey G J, Warrener P, Camara M M, Bonnell J, Fleming R, Bezabeh B, Dimasi N, et al. Sci Transl Med. 2014;6:262r.



THE MECHANISMS OF ALS-4 -


ANTI-GOLDEN PIGMENT AGENT



- Staphyloxanthin is the golden yellow pigment of *S. aureus*
- The pigment protects the bacteria against oxidative stress produced by our immune cells.
- ALS-4 is intended to suppress one of the key enzymes in the pigment production process
- *S. aureus* without pigments are more susceptible to host immune clearance

mBio (8(5): e01224, 2017))






ALS-4 is observed to reduce bacterial load in mice



MECHANISM OF ALS-2 AND ALS-3

ALS-2 is being developed to reduce virulence gene production



ALS-3: An antibiotic-potentiating compound by using a non-antibiotic approach



AWARD WINNING CONCEPT AT ICPIC IN GENEVA, 2017-



This is the first time **chemical genetics** have been applied in an attempt to tackle **MRSA infection**. This revolutionary concept and discovery of the applications of chemical genetics, which forms the basis of the discovery of **ALS-2**, **ALS-3** and **ALS-4**, has been highly praised at **the 4th International Conference on Prevention & Infection Control (ICPIC 2017)** in Geneva, Switzerland. The Company's Hong Kong team, led by Dr. Richard KAO, won **First Place** in **the Innovation Academy category** at the conference.

Preclinical Findings


- MRSA has developed resistance to many, if not all, of the existing drugs available for treatment.
- ALS-4 employs a non-antibiotic approach designed to act on a unique therapeutic target to inhibit production of staphyloxanthin, which distinguishes it from other current treatments.
- Studies have shown that staphyloxanthin is an important factor in enabling MRSA bacteria to escape from the immune system.
- ALS-4 has been developed to inhibit production of staphyloxanthin without killing the bacteria, which should enable the immune system to clear MRSA.
- Current Development Status: Lead Optimization and Ph 1 and in preparation for IND filing. Ph 1 clinical trial is expected to commence in 2020.
- ALS-2 and ALS-3, which also employ a non-antibiotic approach for the intended treatment of bacterial infections, are currently under active development and are at Lead Optimization stage.


Treatment of Infections caused by Influenza A Viruses via a Unique Therapeutic Target



ALS-1

- ALS-1 acts on a unique therapeutic target, nucleoproteins, which distinguishes it from all other currently marketed antiviral drugs which currently experience resistance from Influenza A virus.
- Inhibition of virus replication in vitro and outperforms oseltamivir (Tamiflu[®]) with a lower IC50 (half maximal effective concentration).
- Animal studies suggest that ALS-1 has the potential to be developed into a useful anti-influenza therapeutic.
- Current Development Status: Lead Optimization and in preparation for IND filing by 2020/2021





This figure shows the concentration dependence of ALS-1 in reducing the plaque-forming unit (pfu, a measure of number of infectious virus particulates, which represents the in vitro efficacy of the drug) of human H1N1, H3N2 and H5N1 influenza viruses. The IC₅₀ (the concentration of drug at which 50% of the virus is inhibited) for these viruses is between 0.1-1µM. Oseltamivir (curve in red) is included for comparison in terms of in vitro efficacy against H1N1. The curve of ALS-1 is in the left side of the red curve, indicating ALS-1 has a lower IC₅₀.

(Adapted from Nature Biotechnology (28 (6): 600, 2010))

This figure shows that MDCK cells were infected and ALS-1 (1 μ M) was added before infection (-1 h), at the time of infection (0 h) and at 1, 2, 4, 6 and 8 hour after infection as indicated. + = a control without ALS-1. This figure indicates that ALS-1 inhibited viral growth even when added within 6 hours after inoculation of the MDCK cells with the virus, indicating that the antiviral activities of ALS-1 reside on post-entry and post-nuclear events, suggesting that multiple processes involving NP may be affected.

(Adapted from Nature Biotechnology (28 (6): 600, 2010))




Treatment of Endometriosis by a Non-hormonal Approach



ENDOMETRIOSIS

Endometrium outside the uterine cavity

A chronic gynecological disorder affecting 10% of woman during reproductive ages with 176 million known cases worldwideⁱ




Medical Problem chronic pelvic pain/dysmenorrhea Infertility ectopic pregnancy/ miscarriage

> i.Endometriosis.org: Facts about endometriosis, http://endometriosis.org/resources/articles/facts-about-endometriosis/




PATHOPHYSIOLOGY





The figure is modified from Human Reproduction Update, Vol.17, No.6 pp. 829–847, 2011

Current Treatment for Endometriosis









Studies utilizing mouse endometriosis models demonstrated that administration of NLS-1 resulted in greater reductions in the size and weight of lesions than Vitamin E, EGCG or the control without any treatment molecule. Studies utilizing mouse endometriosis models demonstrated that administration of NLS-1 resulted in greater reductions in angiogenesis than Vitamin E, EGCG or the control without any treatment molecule.

(Adapted from Angiogenesis (16:59, 2013))

∧PTORUM


PROPHYLACTICS & THERAPEUTICS

Prevention Treatment Saline Saline Treatment Prevention Saline / EGCG / pro-EGCG Water p.o. Saline / EGCG / Pro-EGCG Water p.o. -1wk 0wk 2wk 6wk -1wk 0wk 4wk Transplantation Saline Transplantation Saline Termination pro-ECCG Termination pro-EGCG EGCG EGCG lesion size (mm²) 20 20 18 18 16 16 14 14 revention 12 12 Treatment 10 10 8 8 Δ 6 6 4 2 0 Saline EGCG pro-EGCG

Data generated by Prof. Wang, Chi Chiu Ronald, Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong




EFFICACY IN AN ANIMAL MODEL



Comparison of the efficacy of different treatment in an experimental endometriosis model

∧ptorum

NLS-1 General & Reproductive Safety



25 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.



Preclinical Findings

- Drug molecule derived from EGCG which is extracted from green tea.
- Intended as non-hormonal treatment for endometriosis.
- Studies in animal models show reductions in development, growth and angiogenesis of endometriosis greater than EGCG.
- Our treatment may provide an alternative to hormonal treatments which typically have undesirable side effects.
- Current Development Status: Lead Optimization and in preparation of IND filing by 2020/2021.

THE END THANK YOU! Q & A

Thomas Lee, Ph.D. Aptorum Therapeutics Limited Unit 232, 12 Science Park W Ave, Hong Kong Science Park Shatin, N.T., Hong Kong T: (852) 3611 9403 F: (852) 3590 5690 Email: <u>thomas.lee@aptorumgroup.com</u>



29

SELECTED INCOME STATEMENT SUMMARY (US GAAP)

	Ten months ended December 31, 2017	Six months ended June 30, 2018
	US\$	US\$
Healthcare services income	-	26,662
Costs of healthcare services	-	22,749
Research and development expenses	2,560,323	1,342,179
General and administrative fees	1,480,093	2,238,025
Legal and professional fees	1,395,490	1,063,032
Other operating expenses	257,177	235,413
Total operating expense	5,693,083	4,901,398
Other income (loss)	3,131,576	-661,206
Net loss attributable to the Company's shareholders	-2,547,462	-5,488,372
Depreciation and amortisation	58,903	209,267

SELECTED BALANCE SHEET ITEMS (US GAAP)

	December 31, 2017	June 30, 2018
	US\$	US\$
Cash and restricted cash	16,725,807	22,927,198
Total current assets	20,283,399	26,371,722
Property, plant and equipment, net	346,587	4,211,321
Intangible assets, net	1,472,707	1,452,486
Total assets	31,559,982	41,465,225
Convertible debts	480,000	15,687,847
Total current liabilities	1,330,734	16,783,641
Total liabilities	1,330,734	16,949,778
Total shareholders' equity	30,229,248	24,515,447
Working capital*	18,952,665	9,588,081

* Total current assets less total current liabilities



30

(US\$) ROUNDED TO THE NEAREST THOUSAND		
Cash and restricted cash, and marketable securities	US\$18,698,000 (as of 12/31/2017)	US\$25,022,000 (as of 6/30/2018)
Intangible assets, net	US\$1,473,000 (as of 12/31/2017)	US\$1,452,000 (as of 6/30/2018)
Operating expenses	US\$5,693,000 (ten months ended 12/31/2017)	US\$4,901,000 (six months ended 6/30/2018)
Convertible debts	US\$480,000 (as of 12/31/2017)	US\$15,688,000 (as of 6/30/2018)

CAPITAL RAISED IN THE PAST 12 MONTHS



IP STATUS OF ALS-1

ALS-1

Exclusively licensed

Exclusively licelise	iu.					
Title	Country	Application No. / Patent No.	Publication No. / Grant Publication No.	Application Date	Expiration date	Status
Antiviral Compounds And Methods Of Making And Using Thereof	US	9212177 (App. No. 12/850,806)	2011/0212975	5 Aug 2010	27 Nov 2031	Granted
Antiviral Compounds And Methods Of Making And Using Thereof	China	201080044361.6	102596946B	5 Aug 2010	5 Aug 2030	Granted
Antiviral Compounds And Methods Of Making	Europe	2462138 (App. No. 10805941.1)	n/a	5 Aug 2010	5 Aug 2030	Granted
Antiviral Compounds And Methods Of Making	Germany	60 2010 019 171.0	n/a	5 Aug 2010	5 Aug 2030	Granted

IP STATUS OF ALS-2 and ALS-3

ALS-2,3

Exclusively licensed

	eu					
Title	Country	Application No. / Patent No.	Publication No. / Grant Publication No.	Application Date	Expiration date	Status
Antimicrobial Compounds And Methods For Use Thereof	US	App. No 16/309,516	Not yet published	13 Dec 2018	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	Europe	App. No 17812663.7	Not yet published	12 Dec 2018	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	Malaysia	App. No 2018002512	Not yet published	12 Dec 2018	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	Singapore	App. No 11201811093R	Not yet published	12 Dec 2018	n/a	Pending

IP STATUS OF ALS-2 and ALS-3

ALS-2,3 cont'd Exclusively licensed

Exclusively license	ea					
Title	Country	Application No. / Patent No.	Publication No. / Grant Publication No.	Application Date	Expiration date	Status
Antimicrobial Compounds And Methods For Use Thereof	China	App. No 201780035312.8	Not yet published	6 Dec 2018	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	Indonesia	App. No PID201900183	Not yet published	9 Jan 2019	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	India	App. No 201927001415	Not yet published	11 Jan 2019	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	Japan	App. No 2018-565820	Not yet published	14 Dec 2018	n/a	Pending
Antimicrobial Compounds And Methods For Use Thereof	Korea	10-2019-7001227	Not yet published	14 Jan 2019	n/a	Pending

IP STATUS OF ALS-4

ALS-4

Exclusively licensed										
Title	Country	Application No. / Patent No.	Publication No. / Grant Publication No.	Application Date	Expiration date	Status				
Compounds And Methods For The Treatment Of Microbial Infections	US	App. No 16/041,836	Not yet published	22 Jul 2018	n/a	Pending				
Compounds Affecting Pigment Production And Methods For Treatment Of Bacterial Diseases	US	App. No 16/041,838	Not yet published	23 Jul 2018	n/a	Pending				



IP STATUS OF NLS-1

NLS-1

Technology 1 – Compound (Exclusively licensed)										
Title	Country	Application No. / Patent No.	Publication No. / Grant Publication No.	Application Date	Expiration date	Status				
Epigallocatechin gallate derivatives for inhibiting proteasome	US	7544816 (App. No. 10/921,332)	US2006/0041010	19 Aug 2004	3 Oct 2025	Granted				
Same as above	US	8193377 (App. No. 11/660,513)	US2008/0176931	15 Aug 2005	26 Nov 2026	Granted				
Same as above	US	8710248 (App. No. 13/416,657)	US2012/0232135	9 Mar 2012	15 Aug 2024	Granted				
Same as above	US	9169230 (App. No. 14/229,315)	US2014/0213802	28 Mar 2014	15 Aug 2024	Granted				
Same as above	China	200580035478.7	CN101072764B	15 Aug 2005	15 Aug 2025	Granted				
Same as above	Europe	1778663 (App. No. 05779886)	n/a	15 Aug 2005	15 Aug 2025	Granted				
Same as above	India	263365 (App. No. 603/KOLNP/2007)	n/a	19 Feb 2007	15 Aug 2025	Granted				
Same as above	Japan	5265915 (App. No. P2007-526180)	P2008-509939A	15 Aug 2005	15 Aug 2025	Granted				

IP STATUS OF NLS-1

NLS-1 cont'd

Technology 2 – Indication for treatment of endodermises (Exclusively licensed)										
Title	Country	Application No. / Patent No.	Publication No. / Grant Publication No.	Application Date	Expiration date	Status				
Prodrug of green tea epigallocatechin-3- gallate (Pro-EGCG) for use in the treatment of endometriosis	US	9713603 (App. No. 14/422,642)	2015/0216841	20 Aug 2013	20 Aug 2033	Granted				
Same as above	US	10188629 (App. No. 15/628,001)	2017/0281591	20 Jun 2017	20 Aug 2033	Granted				
Same as above	US	App. No 16/259,620	n/a	28 Jan 2019	n/a	Pending				
Same as above	China	201380052717.4	104703596A	10 June 2015	n/a	Pending				
Same as above	Hong Kong	15111955.3	1210971	3 Dec 2015	n/a	Pending				

INDEPENDENT NON-EXECUTIVE DIRECTORS



PROFESSOR DOUGLAS ARNER Independent Non-Executive Director

Kerry Holdings Professorin Law, HKU



DR. JUSTIN WU Independent Non-Executive Director

Chief Operating Officer, **CUHK Medical Centre**



DR. MIRKO SCHERER Independent Non-Executive Director

CEO of TVM Capital China

MR. CHARLES BATHURST

Independent Non-Executive Director

Founder of Summerhill Advisors Limited

SCIENTIFIC ADVISORS



DR. NISHANT AGRAWAL

Senior Clinical Advisor

Professor of Surgery, School of Medicine, University of Chicago



HENRY CHAN LIK YUEN

Senior Advisor Associate Dean, Faculty of Medicine, CUHK



DR. PHILIP W.Y. CHIU

Senior Advisor

Professor, Department of Surgery, Institute of Digestive Disease, CUHK



VINCENT MOK CHUNG TONG

Senior Advisor

Head of Division of Neurology, Dept of Medicine & Therapeutics, CUHK



DR. KENNY YU KWOK HEI

Scientific Assessment Committee Member

NIHR Academic Clinical Lecturer, the University of Manchester



DR. **KA-WAI KWOK**

Committee Member Assistant Professor, Department of Mechanical



DR. JASON Y. K. CHAN

Scientific Assessment Committee Member Assistant Professor,

Department of Otorhinolaryngology, CUHK



DR. OWEN KO HO

Scientific Assessment Committee Member

Assistant Professor, Department of Medicine and Therapeutics, CUHK



DR. WAI-LUNG NG

Scientific Assessment Committee Member

Research fellow, Dana-Farber Cancer Institute/ Harvard Medical School



DR. SUNNY WONG HEI

Scientific Assessment Committee Member

Assistant Professor, Department of Medicine and Therapeutics, CUHK



DR. WILLIAM WU KA KEI

Scientific Assessment Committee Member

Associate Professor, Department of Anaesthesia and Intensive Care, CUHK



Scientific Assessment

Engineering, the University of Hong Kong